![Wei Li](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Wei Li
Président chez
CSTONE PHARMACEUTICALS
Fortune : 1 M $ au 31/05/2026
Profil
Wei Li is Chief Executive Officer at QuantX Biosciences US, Inc. Dr. Li is President, Chief Executive Officer & Director at Frontera Therapeutics, Inc. since 2019.
Dr. Li is Chairman at CStone Pharmaceuticals Co. Ltd. since 2018.
Dr. Li is Director at Ivenix, Inc., Shanghai Fangrun Medical Technology Co., Ltd., Medeor Therapeutics, Inc. since 2015, and LifeMine Therapeutics, Inc. Dr. Li is Non-Executive Director at Sirius Therapeutics since 2025.
Dr. Li is Founding Partner at Creacion Ventures Management LLC since 2020.
Dr. Li is Manager at Creacion Ventures GP.
I LLC.
Former positions include Chief Executive Officer & Director at AltheaDx, Inc., Director at Tunitas Therapeutics, Inc. and TCR² Therapeutics, Inc., Director at Kymera Therapeutics, Inc. from 2018 to 2020, Director at Dewpoint Therapeutics, Inc. from 2018 to 2020, Non-Executive Director at Ocumension Therapeutics from 2021 to 2025, Principal at Vertex Pharmaceuticals, Inc. from 1998 to 2001, Associate at Robert W.
Baird & Co., Inc. from 2003 to 2005, Executive Partner at Eight Roads Capital Advisors (Hong Kong) Ltd. from 2013 to 2015, Principal at Merck Serono SA, Board Member at Innovent Biologics, Inc. from 2009 to 2015, Senior Associate at F-Prime, Inc. from 2005 to 2010, and Managing Partner at 6 Dimensions Capital from 2017 to 2020.
Education includes a doctorate from Harvard University conferred in 1998, an undergraduate degree from China University of Science & Technology conferred in 1993, and an MBA from Kellogg School of Management conferred in 2003.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CSTONE PHARMACEUTICALS 0,08 % | 12/06/2026 | 1 229 159 ( 0,08 % ) | 1 M $ | 31/05/2026 |
Postes actifs de Wei Li
| Sociétés | Poste | Début |
|---|---|---|
| CSTONE PHARMACEUTICALS | Président | - |
Frontera Therapeutics, Inc.
 Frontera Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotech company develops rAAV gene therapies to patients | Directeur Général | 01/12/2019 |
Creacion Ventures Management LLC
 Creacion Ventures Management LLC Investment ManagersFinance Creacion Ventures invests in companies located in the United States. The firm targets companies operating in the fields of therapeutics, interventional medical devices, diagnostic products, drug discovery tools and instruments. It provides financing for early stage capital requirements. | Private Equity Investor | 01/04/2020 |
Shanghai Fangrun Medical Technology Co., Ltd.
 Shanghai Fangrun Medical Technology Co., Ltd. Electronic Equipment/InstrumentsElectronic Technology Manufactures pharmaceutical products and medical equipment | Directeur/Membre du Conseil | - |
Creacion Ventures GP I LLC | Corporate Officer/Principal | - |
LifeMine Therapeutics, Inc.
 LifeMine Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs from fungi which aims to cure untreatable and significant chronic diseases | Directeur/Membre du Conseil | - |
Medeor Therapeutics, Inc.
 Medeor Therapeutics, Inc. BiotechnologyHealth Technology Develops cellular immunotherapies for organ transplant recipients | Directeur/Membre du Conseil | 01/09/2015 |
Ivenix, Inc.
 Ivenix, Inc. Medical SpecialtiesHealth Technology Operates as a medical device company | Directeur/Membre du Conseil | - |
QuantX Biosciences US, Inc.
 QuantX Biosciences US, Inc. BiotechnologyHealth Technology Operates as an emerging computation-powered small molecule drug discovery company | Directeur Général | - |
Anciens postes connus de Wei Li
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░░░░ ░░░░░░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░ ░░░░░░░░░░ ░░░░░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░ ░░░░░░░ ░░░░░░░░ ░░░░░ ░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Wei Li
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
93
Relations au 1er degré
25
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 25 |
|---|---|
Vertex Pharmaceuticals, Inc.
 Vertex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops drugs for the treatment of cystic fibrosis | Health Technology |
Ivenix, Inc.
Ivenix, Inc. Medical SpecialtiesHealth Technology Operates as a medical device company | Health Technology |
AltheaDx, Inc.
 AltheaDx, Inc. Medical SpecialtiesHealth Technology Operates as a commercial stage molecular diagnostics company | Health Technology |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Robert W. Baird & Co., Inc. /Venture Partners/
 Robert W. Baird & Co., Inc. /Venture Partners/ Investment ManagersFinance Baird Capital invests in middle market companies located in the United States with annual revenues of USD 5 - 25 million. The firm focuses on B2B technology & services sector. It participates in early to growth stage transactions with an investment size ranging from USD 15 to 25 million. It acquires majority and minority interest and also takes a seat on the board of directors. | Finance |
Eight Roads Capital Advisors (Hong Kong) Ltd.
 Eight Roads Capital Advisors (Hong Kong) Ltd. Investment ManagersFinance Eight Roads Capital invests in companies located in China. The firm target companies operating in the fields of therapeutics, healthcare services, healthcare IT, digital health, and medical technology sectors. It provides financing for seed, early, and later stage capital requirements. | Finance |
Merck Serono SA
 Merck Serono SA Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops drugs for reproductive and metabolism | Health Technology |
Tunitas Therapeutics, Inc.
 Tunitas Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops protein therapeutics for the treatment of allergy | Health Technology |
China University of Science & Technology
 China University of Science & Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Innovent Biologics, Inc.
 Innovent Biologics, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures biopharmaceutical products | Health Technology |
Kellogg School of Management
 Kellogg School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Impresa Management LLC
 Impresa Management LLC Investment ManagersFinance F-Prime invests in companies located in Asia, Europe, North America and South America. The firm targets companies operating in the fields of life sciences, technology, healthtech & services and crypto sectors. It provides financing for seed, early and later stage transactions. | Finance |
6 Dimensions Capital
 6 Dimensions Capital Investment ManagersFinance 6 Dimensions Capital invests in early and growth stage companies in China, the U.S. and globally. The firm focuses on sectors such as biologics, small molecules, medical devices, diagnostics, medical services and healthcare IT. | Finance |
Shanghai Fangrun Medical Technology Co., Ltd.
Shanghai Fangrun Medical Technology Co., Ltd. Electronic Equipment/InstrumentsElectronic Technology Manufactures pharmaceutical products and medical equipment | Electronic Technology |
Medeor Therapeutics, Inc.
Medeor Therapeutics, Inc. BiotechnologyHealth Technology Develops cellular immunotherapies for organ transplant recipients | Health Technology |
CStone Pharmaceuticals Co. Ltd.
 CStone Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Develops therapeutic treatments for oncology, cardiovascular diseases, rheumatoid arthritis, hematology and autoimmune diseases | Health Technology |
LifeMine Therapeutics, Inc.
LifeMine Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs from fungi which aims to cure untreatable and significant chronic diseases | Health Technology |
TCR2 Therapeutics, Inc.
 TCR2 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage cell therapy company which engages in the development of biological drugs and engineering T-cells for cancer therapy | Health Technology |
Kymera Therapeutics, Inc.
 Kymera Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops immunology medicines for health problems | Health Technology |
Dewpoint Therapeutics, Inc.
 Dewpoint Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biomolecular condensates biotechnology company | Health Technology |
Ocumension Therapeutics
 Ocumension Therapeutics Miscellaneous Commercial ServicesCommercial Services Operates as an ophthalmic pharmaceutical platform company that develops drugs | Commercial Services |
Creacion Ventures Management LLC
Creacion Ventures Management LLC Investment ManagersFinance Creacion Ventures invests in companies located in the United States. The firm targets companies operating in the fields of therapeutics, interventional medical devices, diagnostic products, drug discovery tools and instruments. It provides financing for early stage capital requirements. | Finance |
Creacion Ventures GP I LLC | |
Frontera Therapeutics, Inc.
Frontera Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotech company develops rAAV gene therapies to patients | Health Technology |
QuantX Biosciences US, Inc.
QuantX Biosciences US, Inc. BiotechnologyHealth Technology Operates as an emerging computation-powered small molecule drug discovery company | Health Technology |
